Edwards Lifesciences

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2022

Retrieved on: 
Tuesday, April 19, 2022

IRVINE, Calif., April 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022, and will host a conference call at 5:00 p.m.

Key Points: 
  • IRVINE, Calif., April 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022, and will host a conference call at 5:00 p.m.
  • The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com .
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

California Life Sciences Releases 2021 Sector Report

Retrieved on: 
Wednesday, April 13, 2022

SOUTH SAN FRANCISCO, SAN DIEGO, LOS ANGELES, SACRAMENTO, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- California Life Sciences (CLS), the states most influential and impactful life sciences membership organization, today released its annual report showing that Californias life sciences sector directly employed 313,230 people, attracted $12.5 billion in venture capital (VC) and received $5.0 billion in funding from the NIH.

Key Points: 
  • SOUTH SAN FRANCISCO, SAN DIEGO, LOS ANGELES, SACRAMENTO, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- California Life Sciences (CLS), the states most influential and impactful life sciences membership organization, today released its annual report showing that Californias life sciences sector directly employed 313,230 people, attracted $12.5 billion in venture capital (VC) and received $5.0 billion in funding from the NIH.
  • The 2021 Sector Reporthighlights these key findings and other economic, employment and academic contributions to the state of California.
  • Our annual Sector Report provides a wholistic assessment of our complex ecosystem and our states overall impact to the broader industry and economy, said Mike Guerra, president and CEO of California Life Sciences.
  • California Life Sciences (CLS) is the states most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline.

Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.
  • The abstract highlights the new clinical data from Enzychems Phase 2 US clinical trial evaluating EC-18 in head and neck cancer (HNC) patients with chemoradiation-induced oral mucositis (CRIOM).
  • I am honored to present Enzychems clinical data at the MASCC/ISOO 2022 annual meeting, said Dr. Christina Henson.
  • Enzychem is headquartered in South Korea, with an office in the United States.

Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting

Retrieved on: 
Wednesday, April 6, 2022

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.
  • The abstract highlights the new clinical data from Enzychems Phase 2 US clinical trial evaluating the effect of EC-18 on severe oral mucositis (SOM) development in chemoradiation-treated head and neck cancer patients.
  • Dr. Christina Henson, a board-certified Radiation Oncologist and Residency Program Director for Radiation Oncology at the University of Oklahoma will present the following abstract.
  • Enzychem is headquartered in South Korea, with an office in the United States.

EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES

Retrieved on: 
Thursday, March 31, 2022

The MITRIS RESILIA valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve.

Key Points: 
  • The MITRIS RESILIA valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve.
  • The introduction of the MITRIS RESILIA valve completes the portfolio of surgical heart valve innovations incorporating the advanced RESILIA tissue, including an aortic valve, an aortic valved conduit and now a mitral valve.
  • In addition to FDA approval, the MITRIS RESILIA valve has also received regulatory approval in Japan, Canada, and other countries globally.
  • Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Carpentier-Edwards PERIMOUNT, MITRIS, MITRIS RESILIA, PERIMOUNT, and RESILIA are trademarks of Edwards Lifesciences Corporation.

indie Semiconductor Announces Retirement of Bill Woodward and Appointment of Diane Biagianti to Its Board of Directors

Retrieved on: 
Tuesday, March 29, 2022

indie Semiconductor (Nasdaq: INDI), an Autotech solutions innovator, today announced that Bill Woodward has retired and Diane Biagianti has been appointed to its board of directors.

Key Points: 
  • indie Semiconductor (Nasdaq: INDI), an Autotech solutions innovator, today announced that Bill Woodward has retired and Diane Biagianti has been appointed to its board of directors.
  • Bill is a visionary and instilled tenacity, a customer-centric focus and financial discipline into our DNA from the launch of indie back in 2007.
  • We are delighted to welcome Diane to our board of directors, said David Aldrich, indies chairman of the board.
  • I am excited to be joining indies board of directors at this key growth stage, said Biagianti.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Notice of Allowance for the Company’s United States Patent Claims on Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy

Retrieved on: 
Tuesday, March 29, 2022

This new patent builds upon the 8 US patents BioCurity exclusively controls related to its novel drug development.

Key Points: 
  • This new patent builds upon the 8 US patents BioCurity exclusively controls related to its novel drug development.
  • Globally, it is estimated that 6 million of the 18 million annually diagnosed new cancer patients receive radiation.
  • BioCurity is a preclinical biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy.
  • Burning and blistering and permanent scarring of the skin can also result for cancer patients undergoing radiation therapy.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects

Retrieved on: 
Thursday, March 10, 2022

BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

Key Points: 
  • BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.
  • BioCurity offers the potential to prevent the often-devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients.
  • BioCurity is a global leader in drug development using cerium oxide nanoparticles to mitigate the side effects associated with radiation therapy.
  • BioCurity is biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy.

Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Retrieved on: 
Wednesday, March 9, 2022

An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.

Key Points: 
  • An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.
  • If a safety issue was noted, the iDSMB was instructed to unblind the treatment assignments to ascertain if the adverse event (AE) was associated with the study drug.
  • Since no safety issues were identified at the end of Stage 1, Stage 2 commenced using 2000 mg of the study drug, consistent with a positive safety outcome.
  • Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases.

Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Retrieved on: 
Wednesday, March 2, 2022

Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.
  • To reinforce such corporate initiatives, and to start supporting the companys next stage activities, Enzychem has formed the Corporate Advisory Committee.
  • The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives.
  • Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones.